JP2011500544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500544A5 JP2011500544A5 JP2010528478A JP2010528478A JP2011500544A5 JP 2011500544 A5 JP2011500544 A5 JP 2011500544A5 JP 2010528478 A JP2010528478 A JP 2010528478A JP 2010528478 A JP2010528478 A JP 2010528478A JP 2011500544 A5 JP2011500544 A5 JP 2011500544A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- nitrogen
- heterocyclic
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 62
- 150000001875 compounds Chemical class 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- -1 C 1-6 alkanol Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97955507P | 2007-10-12 | 2007-10-12 | |
| US60/979,555 | 2007-10-12 | ||
| GBGB0720041.3A GB0720041D0 (en) | 2007-10-12 | 2007-10-12 | New Compounds |
| GB0720041.3 | 2007-10-12 | ||
| US6117808P | 2008-06-13 | 2008-06-13 | |
| US61/061,178 | 2008-06-13 | ||
| PCT/GB2008/003418 WO2009047506A1 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500544A JP2011500544A (ja) | 2011-01-06 |
| JP2011500544A5 true JP2011500544A5 (cg-RX-API-DMAC7.html) | 2011-10-20 |
| JP5497648B2 JP5497648B2 (ja) | 2014-05-21 |
Family
ID=38788133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528478A Expired - Fee Related JP5497648B2 (ja) | 2007-10-12 | 2008-10-10 | タンパク質チロシンキナーゼインヒビターとしての二環式ヘテロ環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8076354B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2197880B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5497648B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008309418B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2701865C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1117139T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2197880T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2559685T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0720041D0 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20160002T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE026275T2 (cg-RX-API-DMAC7.html) |
| ME (1) | ME02373B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2197880T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2197880E (cg-RX-API-DMAC7.html) |
| RS (1) | RS54518B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2197880T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009047506A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006706A (es) * | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| FR3000746A1 (fr) | 2013-01-04 | 2014-07-11 | Centre Nat Rech Scient | Peptide pour son utilisation dans le traitement des neuronopathies motrices |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| RU2658821C1 (ru) | 2014-08-18 | 2018-06-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль моноциклического производного пиридина и ее кристалл |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| CA2974937C (en) | 2015-03-25 | 2023-09-05 | National Cancer Center | Therapeutic agent for bile duct cancer |
| WO2017049498A1 (zh) * | 2015-09-23 | 2017-03-30 | 前湾医药科技（深圳）有限公司 | 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用 |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| CN120478294A (zh) | 2015-10-16 | 2025-08-15 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN115177619A (zh) | 2015-12-17 | 2022-10-14 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| AU2018352142B2 (en) * | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| CU20200041A7 (es) * | 2017-10-24 | 2021-03-11 | Bayer Ag | Amidas de imidazopiridina sustituidas |
| KR20200135945A (ko) | 2018-03-28 | 2020-12-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포 암종 치료제 |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12378241B2 (en) | 2019-07-26 | 2025-08-05 | Cgenetech (Suzhou,China) Co., Ltd. | Pyridine derivative as FGFR and VEGFR dual inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2022213682C1 (en) * | 2021-01-26 | 2025-04-17 | Cgenetech (Suzhou, China) Co., Ltd | Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2025140655A1 (en) * | 2023-12-30 | 2025-07-03 | Fujian Haixi Pharmaceuticals Co., Ltd. | Heteroaryl compounds as multi-target protein kinase inhibitors |
| WO2025140656A1 (en) * | 2023-12-30 | 2025-07-03 | Fujian Haixi Pharmaceuticals Co., Ltd. | Heteroaryl compounds as multi-target protein kinase inhibitors |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| EP0308020A3 (en) | 1987-09-18 | 1990-12-05 | Merck & Co. Inc. | 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5554630A (en) | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| US5840732A (en) | 1994-06-20 | 1998-11-24 | Takeda Chemical Industries Ltd. | Imidazopyridine or imidazopyrimidine compounds, their production and use |
| JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| WO2000012089A1 (en) | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| JP4228332B2 (ja) | 1998-01-28 | 2009-02-25 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | アゾロトリアジン類およびアゾロピリミジン類 |
| US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6316444B1 (en) | 1999-06-30 | 2001-11-13 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| US6329380B1 (en) * | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
| GB9927687D0 (en) | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| EP1261607B1 (en) | 2000-03-01 | 2008-11-12 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
| AU2001272098A1 (en) | 2000-03-09 | 2001-09-17 | Sanofi-Aventis Deutschland Gmbh | Therapeutic uses of PPAR mediators |
| US20020041880A1 (en) | 2000-07-05 | 2002-04-11 | Defeo-Jones Deborah | Method of treating cancer |
| WO2002012238A2 (en) | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| GB0027561D0 (en) | 2000-11-10 | 2000-12-27 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| US20020107262A1 (en) | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| SE0100567D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| IL156784A0 (en) | 2001-02-20 | 2004-02-08 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| DE10117183A1 (de) | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
| ATE402164T1 (de) | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| AU2003227437A1 (en) | 2002-04-23 | 2003-11-10 | Shionogi And Co., Ltd. | PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| WO2003092595A2 (en) | 2002-05-02 | 2003-11-13 | Merck & Co., Inc | Tyrosine kinase inhibitors |
| AUPS251402A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Kinase inhibitors |
| US7259179B2 (en) | 2002-05-23 | 2007-08-21 | Cytopia Research Pty Ltd | Kinase inhibitors |
| GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| DE60319820T2 (de) | 2002-06-04 | 2009-03-26 | Schering Corp. | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien |
| US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| GB0223349D0 (en) | 2002-10-08 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004035579A1 (ja) | 2002-10-15 | 2004-04-29 | Takeda Pharmaceutical Company Limited | イミダゾピリジン誘導体、その製造法および用途 |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| AU2003298942A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7826979B2 (en) | 2003-02-14 | 2010-11-02 | Vertex Pharmaceuticals Incorporated | Method of modeling complex formation between a query ligan and a target molecule |
| US7476670B2 (en) | 2003-02-18 | 2009-01-13 | Aventis Pharma S.A. | Purine derivatives, method for preparing, pharmaceutical compositions and novel use |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| EP1664021A1 (en) * | 2003-08-21 | 2006-06-07 | OSI Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors |
| EP1658289B1 (en) | 2003-08-21 | 2009-03-18 | OSI Pharmaceuticals, Inc. | 3-substituted imidazopyridine-derivatives as c-kit inhibitors |
| US7442709B2 (en) | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
| BRPI0417345A (pt) | 2003-12-03 | 2007-03-13 | Cytopia Res Pty Ltd | compostos inibidores de quìnase baseados em azola, composições e seus usos |
| EP1711496A4 (en) | 2004-01-28 | 2009-02-11 | Smithkline Beecham Corp | THIAZOLE COMPOUNDS |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| WO2005108399A1 (ja) | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US7718801B2 (en) | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| CA2589770A1 (en) | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
| US20080167314A1 (en) | 2004-12-28 | 2008-07-10 | Osamu Uchikawa | Condensed Imidazole Compound And Use Thereof |
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| WO2006094235A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
| FR2884821B1 (fr) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| US8119643B2 (en) | 2006-03-20 | 2012-02-21 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| CA2646886A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| ITVA20060041A1 (it) | 2006-07-05 | 2008-01-06 | Dialectica Srl | Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington |
| TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1882475A1 (en) | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| MX2009006706A (es) * | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| MX2009010728A (es) | 2007-04-03 | 2009-10-26 | Array Biopharma Inc | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. |
| CN101765585B (zh) | 2007-06-12 | 2017-03-15 | 尔察祯有限公司 | 抗菌剂 |
| US20090005374A1 (en) | 2007-06-26 | 2009-01-01 | Melvin Jr Lawrence S | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
-
2007
- 2007-10-12 GB GBGB0720041.3A patent/GB0720041D0/en not_active Ceased
-
2008
- 2008-10-10 DK DK08806556.0T patent/DK2197880T3/en active
- 2008-10-10 RS RS20160029A patent/RS54518B1/sr unknown
- 2008-10-10 HR HRP20160002TT patent/HRP20160002T1/hr unknown
- 2008-10-10 AU AU2008309418A patent/AU2008309418B2/en not_active Ceased
- 2008-10-10 PL PL08806556T patent/PL2197880T3/pl unknown
- 2008-10-10 CA CA2701865A patent/CA2701865C/en active Active
- 2008-10-10 ME MEP-2016-3A patent/ME02373B/me unknown
- 2008-10-10 HU HUE08806556A patent/HUE026275T2/en unknown
- 2008-10-10 WO PCT/GB2008/003418 patent/WO2009047506A1/en not_active Ceased
- 2008-10-10 PT PT88065560T patent/PT2197880E/pt unknown
- 2008-10-10 JP JP2010528478A patent/JP5497648B2/ja not_active Expired - Fee Related
- 2008-10-10 US US12/682,508 patent/US8076354B2/en active Active
- 2008-10-10 EP EP08806556.0A patent/EP2197880B1/en active Active
- 2008-10-10 SI SI200831563T patent/SI2197880T1/sl unknown
- 2008-10-10 ES ES08806556.0T patent/ES2559685T3/es active Active
-
2011
- 2011-10-18 US US13/275,786 patent/US8859583B2/en active Active
-
2016
- 2016-01-18 CY CY20161100043T patent/CY1117139T1/el unknown